Testing effectiveness (Phase 2)Ended earlyNCT01023880
What this trial is testing
Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy
Who this might be right for
Multiple Myeloma
Cephalon 62